id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2004-E-0269-0017,FDA,FDA-2004-E-0269,Letter from FDA CDER to the U.S. Patent and Trademark Office,Other,Letter(s),2006-09-08T04:00:00Z,2006,9,,,2025-11-18T19:13:09Z,,0,0,0900006480472208
FDA-2004-E-0269-0016,FDA,FDA-2004-E-0269,Letter from U.S. Patent and Trademark Office and FDA CDER,Other,Letter(s),2006-06-20T04:00:00Z,2006,6,,,2025-11-18T19:09:15Z,,0,0,0900006480472207
FDA-2004-E-0269-0015,FDA,FDA-2004-E-0269,Determination of Regulatory Review Period for Purposes of Patent Extension; SURPASS,Notice,General Notice,2006-02-15T05:00:00Z,2006,2,2006-02-03T05:00:00Z,,2025-11-18T19:06:04Z,E6-1434,0,0,0900006480472206
FDA-2004-E-0269-0014,FDA,FDA-2004-E-0269,Letter from FDA CDER to U.S. Patent and Trademark Office,Other,Letter(s),2006-01-11T05:00:00Z,2006,1,,,2025-11-18T18:59:52Z,,0,0,0900006480472205